Valeo Pharma Inc
TSX:VPH
Balance Sheet
Balance Sheet Decomposition
Valeo Pharma Inc
Valeo Pharma Inc
Balance Sheet
Valeo Pharma Inc
| Oct-2016 | Oct-2017 | Oct-2018 | Oct-2019 | Oct-2020 | Oct-2021 | Oct-2022 | Oct-2023 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
0
|
0
|
0
|
0
|
3
|
2
|
23
|
8
|
|
| Cash |
0
|
0
|
0
|
0
|
3
|
2
|
23
|
8
|
|
| Total Receivables |
3
|
1
|
1
|
1
|
1
|
2
|
5
|
7
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
1
|
1
|
5
|
6
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
1
|
1
|
8
|
10
|
10
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
1
|
3
|
1
|
|
| Total Current Assets |
3
|
1
|
1
|
2
|
5
|
12
|
41
|
25
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
1
|
2
|
2
|
3
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
1
|
2
|
2
|
3
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
|
| Intangible Assets |
1
|
2
|
2
|
4
|
5
|
7
|
15
|
13
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
4
N/A
|
3
-20%
|
3
0%
|
6
+72%
|
11
+89%
|
21
+92%
|
58
+177%
|
41
-29%
|
|
| Liabilities | |||||||||
| Accounts Payable |
1
|
1
|
2
|
4
|
4
|
10
|
12
|
11
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Debt |
0
|
1
|
1
|
0
|
0
|
0
|
1
|
3
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
5
|
0
|
2
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
4
|
|
| Total Current Liabilities |
1
|
2
|
3
|
4
|
4
|
15
|
15
|
20
|
|
| Long-Term Debt |
2
|
3
|
1
|
1
|
3
|
3
|
61
|
60
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
|
| Total Liabilities |
3
N/A
|
6
+82%
|
5
-21%
|
6
+23%
|
8
+35%
|
19
+140%
|
76
+301%
|
82
+7%
|
|
| Equity | |||||||||
| Common Stock |
0
|
0
|
5
|
9
|
15
|
25
|
26
|
32
|
|
| Retained Earnings |
1
|
3
|
6
|
9
|
13
|
25
|
52
|
79
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
1
|
2
|
3
|
4
|
5
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
3
|
3
|
|
| Total Equity |
1
N/A
|
3
N/A
|
1
+47%
|
0
+98%
|
3
N/A
|
2
-33%
|
18
N/A
|
40
-126%
|
|
| Total Liabilities & Equity |
4
N/A
|
3
-20%
|
3
0%
|
6
+72%
|
11
+89%
|
21
+92%
|
58
+177%
|
41
-29%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
31
|
31
|
45
|
50
|
64
|
79
|
82
|
99
|
|